SCHEMBL93575

SCHEMBL93575

FC(F)(Cl)C(F)(F)OCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Norflurane SCHEMBL3953734 0.85
SCHEMBL6284827 0.77
SCHEMBL29077352 0.77
SCHEMBL9345901 0.72
SCHEMBL8766236 0.72
SCHEMBL9493379 0.69
SCHEMBL9391444 0.69
SCHEMBL5376470 0.67
SCHEMBL8968616 0.67
SCHEMBL6359912 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3322 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202699-A1 COMPOSITIONS FOR THE TREATMENT OF VIRAL PULMONARY INFECTIONS STROHECKER PAUL (US) 2022-06-30 US claimed
US-20220202700-A1 COMPOSITIONS FOR THE TREATMENT OF VIRAL PULMONARY INFECTIONS STROHECKER PAUL (US) 2022-06-30 US claimed
EP-4747218-A1 METHODS, COMPOSITIONS AND USES RELATED TO THE TREATMENT AND PREVENTION OF LEIGH'S SYNDROME Stealth BioTherapeutics Inc. (US) 2026-05-27 EP disclosed
WO-2026107328-A1 AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS SEPTERNA, INC. (US) 2026-05-21 WO disclosed
US-12630632-B2 Bispecific HER2 and CD3 binding molecules MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2026-05-19 US disclosed
EP-4731237-A1 COMBINATION THERAPY FOR THE TREATMENT OF FRIEDREICH'S ATAXIA Stealth BioTherapeutics Inc. (US) 2026-04-29 EP disclosed
US-12612420-B2 Arginase inhibitors and methods of use thereof MOLECURE S.A. (PL) 2026-04-28 US disclosed
US-20260109711-A1 MACROCYCLIC SULFONAMIDE MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2026-04-23 US disclosed
US-12595244-B2 Small molecule inhibitors of mammalian SLC6A19 function JNANA THERAPEUTICS INC. (US) 2026-04-07 US disclosed
US-20260083714-A1 DOSING REGIMEN FOR TREATING PKU WITH A PIPERIDINE INHIBITOR OF SLC6A19 FUNCTION JNANA THERAPEUTICS INC (US) 2026-03-26 US disclosed
EP-4215194-B1 COMBINATION THERAPY OF AT1 R BLOCKER AND CCR2 INHIBITOR FOR THE TREATMENT, AMELIORATION OR PREVENTION OF A KIDNEY DISEASE DIMERIX BIOSCIENCE PTY LTD (AU) 2026-03-25 EP disclosed
WO-1994020069-A1 PULMONARY ADMINISTRATION OF GRANULOCYTE COLONY STIMULATING FACTOR AMGEN INC. (US) 1994-09-15 WO disclosed
EP-0613683-A1 Pharmaceutical compositions for systemic administration of erythropoietin via the respiratory system AMGEN INC. (US) 1994-09-07 EP disclosed
WO-1994017822-A1 PULMONARY ADMINISTRATION OF sCR1 AND OTHER COMPLEMENT INHIBITORY PROTEINS T CELL SCIENCES, INC. (US) 1994-08-18 WO disclosed
WO-1994017784-A1 PULMONARY ADMINISTRATION OF ERYTHROPOIETIN AMGEN INC. (US) 1994-08-18 WO disclosed
US-5284656-A Directing neutrophil stimulating amount of G CSF into mouth while inhaling AMGEN INC. (US) 1994-02-08 US disclosed
CN-1066192-A The pulmonary administration of granulocyte colony stimulating factor (G-CSF) AMGEN INC (US) 1992-11-18 CN disclosed
WO-1992016192-A1 PULMONARY ADMINISTRATION OF GRANULOCYTE COLONY STIMULATING FACTOR AMGEN INC. (US) 1992-10-01 WO disclosed
EP-0505123-A1 Pulmonary administration of granulocyte colony stimulating factor AMGEN INC. (US) 1992-09-23 EP disclosed
US-4289893-A 2,5-Inter-O-phenylene-3,4-dinor-PGF2 compounds THE UPJOHN COMPANY (US) 1981-09-15 US disclosed